The evaluation of a newly developed antigen test (QuickNavi™-COVID19 Ag) for SARS-CoV-2: A prospective observational study in Japan.

The evaluation of a newly developed antigen test (QuickNavi™-COVID19 Ag) for SARS-CoV-2: A prospective observational study in Japan.
复制标题

DOI:
10.1016/j.jiac.2021.02.029
复制
发表时间:
2021-06
期刊:
Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy
影响因子:
--
通讯作者:
Suzuki H
Suzuki H
中科院分区:
其他
文献类型:
--
作者:
Takeuchi Y;Akashi Y;Kato D;Kuwahara M;Muramatsu S;Ueda A;Notake S;Nakamura K;Ishikawa H;Suzuki H

文献摘要

参考文献

被引文献

相似文献

Several antigen tests for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been developed worldwide, but their clinical utility has not been well established. In this study, we evaluated the analytical and clinical performance of QuickNavi™-COVID19 Ag, a newly developed antigen test in Japan. This prospective observational study was conducted at a PCR center between October 7 and December 5, 2020. The included patients were referred from a local public health center and 89 primary care facilities. We simultaneously obtained two nasopharyngeal samples with flocked swabs; one was used for the antigen test and the other for real-time reverse transcription PCR (RT-PCR). Using the results of real-time RT-PCR as a reference, the performance of the antigen test was evaluated. A total of 1186 patients were included in this study, and the real-time RT-PCR detected SARS-CoV-2 in 105 (8.9%). Of these 105 patients, 33 (31.4%) were asymptomatic. The antigen test provided a 98.8% (95% confidence interval [CI]: 98.0%–99.4%) concordance rate with real-time RT-PCR, along with a sensitivity of 86.7% (95% CI: 78.6%–92.5%) and a specificity of 100% (95% CI: 99.7%–100%). False-negatives were observed in 14 patients, 8 of whom were asymptomatic and had a low viral load (cycle threshold (Ct) > 30). In symptomatic patients, the sensitivity was 91.7% (95% CI: 82.7%–96.9%). QuickNavi™-COVID19 Ag showed high specificity and sufficient sensitivity for the detection of SARS-CoV-2. This test is a promising potential diagnostic modality especially in symptomatic patients.
DOI: 10.1093/cid/ciaa638
发表时间: 2020-11-15
影响因子: 11.8
作者:
Bullard, Jared;Dust, Kerry;Poliquin, Guillaume
通讯作者: Poliquin, Guillaume
DOI: 10.1186/s12985-020-01452-5
发表时间: 2020-11-13
期刊: Virology journal
影响因子: 4.8
作者:
Chaimayo C;Kaewnaphan B;Tanlieng N;Athipanyasilp N;Sirijatuphat R;Chayakulkeeree M;Angkasekwinai N;Sutthent R;Puangpunngam N;Tharmviboonsri T;Pongraweewan O;Chuthapisith S;Sirivatanauksorn Y;Kantakamalakul W;Horthongkham N
通讯作者: Horthongkham N
DOI: 10.1001/jamainternmed.2020.3862
发表时间: 2020-11-01
影响因子: 39
作者:
Lee, Seungjae;Kim, Tark;Kim, Tae Hyong
通讯作者: Kim, Tae Hyong
DOI: 10.1128/jcm.02055-05
发表时间: 2006-06-01
影响因子: 9.4
作者:
Daley, Peter;Castriciano, Santina;Smieja, Marek
通讯作者: Smieja, Marek
DOI: 10.1126/sciadv.abd5393
发表时间: 2021-01
期刊: Science advances
影响因子: 13.6
作者:
Larremore DB;Wilder B;Lester E;Shehata S;Burke JM;Hay JA;Tambe M;Mina MJ;Parker R
通讯作者: Parker R